]>
IRCT20150310021420N5 IRCT 2021-06-14 Tehran University of Medical Sciences FSH administration for triggering final oocyte maturation in improving ART outcome Effect of simultanious administration of FSH and hCG for triggering on oocyte quality and ART outcome in antagonist protocol 2021-05-20 anticipated 110 Complete https://irct.ir/trial/18779 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: According to Stratified Block randomization, the samples will be divided into two groups of intervention and control. The number of blocks will be 6. The mentioned list will be generated by using the "www.sealedenvelope.com" site. The random allocation list is solely available to the epidemiologist. For the Concealment of the random allocation process, treatments will be written on 110 cards, respectively. then the cards are placed inside sealed envelopes. When the physician announces the eligibility of a patient, the methodologist will provide the physician with the envelope, Blinding description: The assessor of the final outcome (oocyte quality), who is the embryologist, is unaware of the type of cycle regimen. The data analyzer is also unaware of the type of intervention. 3 femaleInfertility. Intervention 1: Intervention group: The patients enter antagonist cycle and after frequent follicular monitoring and defining the triggering time . When at least two oocytes were seen HCG 10000+FSH450I.U were injected. Intervention 2: Control Group: The patients enter antagonist cycle and after frequent follicular monitoring and defining the triggering time . When atleast two oocytes were seen, HCG 10000 was injected. Yes - There is a plan to make this available What will be shared: All data set and study protocol potentially after nonidentification of patients can be shared. When: 6 months after publication of manuscript To whom: Academic and scientific researchesrs Conditions: It is usable by mentioning the reference Where to obtain: It should be requested by Email m_fmojtahedi@yahoo.com Dr.Maryam farid Mojtahedi How to obtain: If ّit be requested by Email,it will be answered in one month Comments:
public Maryam Faridmojtahedi
Arash Women's Hospital, Resalt highway, Tehranpars, Rashid Ave.
Tehran Iran (Islamic Republic of) 1653915981 +98 21 7771 9922 m_fmojtahedi@yahoo.com Tehran University of Medical Sciences scientific Maryam Faridmojtahedi
Arash Women's Hospital, Resalt highway, Tehranpars, Rashid Ave.
Tehran Iran (Islamic Republic of) 1653915981 +98 21 7771 9922 m_fmojtahedi@yahoo.com Tehran University of Medical Sciences Iran (Islamic Republic of) age between 18 and 38 third day FSH below10IU/ml and AFC more than 5 in each ovary normal uterine cavity antagonist protocol IVF cycles 18 years 38 years Female Estradiol at day of trigger more than 4500IU/l Cancellation of oocyte retrieval due to cycle cancellation or changing to IUI History of more than 2 failed IVF/ICSI Severe male factor N97.9 Female infertility, unspecified Treatment - Drugs Treatment - Drugs Intervention group: The patients enter antagonist cycle and after frequent follicular monitoring and defining the triggering time . When at least two oocytes were seen HCG 10000+FSH450I.U were injected. Control Group: The patients enter antagonist cycle and after frequent follicular monitoring and defining the triggering time . When atleast two oocytes were seen, HCG 10000 was injected. Oocyte quality. Timepoint: Day of ovarian puncture. Method of measurement: gardner scale by microscope. Clinical pregnancy. Timepoint: 28 days after transfer. Method of measurement: vaginal ultrasound and observation of fetal heart beat. Ongoing pregnancy. Timepoint: after first trimester. Method of measurement: sonography and observation of alive fetus. Tehran University of Medical Sciences Approved 2017-02-01 Ethics committee of School of Medicine - Tehran University of Medical Sciences Poorsina st - Qods st - enghelab st - Tehran-Iran Tehran Tehran Iran (Islamic Republic of)